Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Indications For Sunovion’s Latuda Mean New Marketing Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

The Japanese pharma gained two more indications for the atypical antipsychotic and hopes to differentiate it by stressing its approval as both a monotherapy and adjunctive therapy to standards of care.

You may also be interested in...

Sunovion Sales Rep Draws FDA Promotional Letter For Declaring Broader Latuda Label Inevitable

While admitting that Sunovion Pharmaceuticals Inc.’s schizophrenia drug Latuda (lurasidone) does not yet have an indication for bipolar I disorder, a sales rep told a psychiatrist it could still be used to treat that condition, FDA’s Office of Prescription Drug Promotion says in a “notice of violation” letter.

Dainippon Sumitomo Rolls Out Latuda; Will Sepracor's $2.6 Billion Sales Force Pay Off?

TOKYO - Dainippon Sumitomo launched its atypical antipsychotic Latuda (lurasidone) in the U.S. Feb. 4, and now the pressure is on to capitalize on the sales force it acquired in the acquisition of Sepracor. Analysts' eyes will be on Latuda's initial sales to gauge the company's acquired ability to market its in-house drugs in the U.S

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts